RECQL1 Antibody

What applications are RECQ1 antibodies suitable for in laboratory research?

RECQ1 antibodies are validated for several key laboratory techniques including Western blotting (WB) and immunocytochemistry/immunofluorescence (ICC/IF). These antibodies can detect human RECQ1 protein in various experimental setups, allowing researchers to investigate protein expression, localization, and interactions . When selecting an antibody, it's important to verify its specificity with human samples, as demonstrated in published studies that have successfully used these antibodies to detect RECQ1 in human cell lines, including both cancer and non-cancer cells . For reproducible results, researchers should validate antibody performance in their specific experimental conditions before conducting full-scale investigations.

What is the biological function of RECQ1 protein that researchers aim to study with these antibodies?

RECQ1 functions as a DNA helicase that exhibits Mg(2+)- and ATP-dependent activity, unwinding single- and double-stranded DNA in a 3'-5' direction . It plays critical roles in multiple DNA maintenance pathways, including:

• Resolution of Holliday junctions during homologous recombination

• Restoration of regressed replication forks

• Restarting stalled replication forks after topoisomerase 1 and 2 lesions

• Protection of nascent DNA strands from degradation during replication stress

• Participation in telomere maintenance, particularly in cells using alternative lengthening of telomeres (ALT)

Researchers use RECQ1 antibodies to track these processes, particularly in understanding how RECQ1 interacts with key DNA repair proteins like PARP1 and XRCC1 to maintain genomic stability.

How does RECQ1 expression vary across different cell types?

Research has shown that RECQ1 expression levels vary significantly across different cell types, with particularly high expression in rapidly dividing cells and multiple cancer cell types. Quantitative analysis revealed that glioblastoma cell lines (M059K, U251, and U87MG) express significantly higher levels of RECQ1 than non-cancerous retina pigmented epithelium cells (RPE1) . In ovarian cancer studies, researchers have used immunohistochemistry to detect varying RECQ1 expression levels across 111 epithelial ovarian cancer patient samples, suggesting its potential use as a prognostic indicator . When designing experiments, researchers should consider these natural variations and include appropriate controls when comparing RECQ1 expression across different cell types.

How does RECQ1 interact with other DNA repair proteins during replication stress?

RECQ1 functions within a network of DNA repair proteins, with key interactions that orchestrate responses to replication stress. The protein physically interacts with:

• PARP1 (poly[ADP-ribose] polymerase 1), which binds to unresected stalled DNA replication forks and recruits XRCC1

• XRCC1, which together with PARP1 and RECQ1 mediates repair and promotes replication restart

• PCNA (proliferating cell nuclear antigen), which associates with RECQ1 at replication sites

• Telomere repeat-binding factor 2 (TRF2), which regulates RECQ1's helicase activity on telomeric substrates

• Protection of telomeres 1 (POT1), which stimulates RECQ1 activity on telomeric substrates containing thymine glycol

These interactions create a functional unit that maintains replication fork stability under stress conditions. RECQ1 depletion studies have shown increased nascent strand degradation, fork stalling, and DNA double-strand break formation, confirming its essential role in this process .

What is the role of RECQ1 in Holliday junction processing?

RECQ1 has been identified as a critical enzyme responsible for ATP-dependent Holliday junction (HJ) branch migration activity in nuclear extracts from proliferating cells . Experimental evidence confirms that:

• Immunopurified FLAG-tagged RECQ1 exhibits ATP-dependent HJ branch migration activity, unlike other tested proteins including RAD54L, RuvBL1, RAD51C, and XRCC3

• RECQ1 actively resolves telomeric D-loops and Holliday junction substrates, particularly in cells using alternative lengthening of telomeres (ALT)

• HeLa cells with reduced RECQ1 levels (via siRNA) show substantially increased sister chromatid exchanges (SCEs), further enhanced by MMC-induced DNA damage

This function positions RECQ1 as a key regulator of recombination-mediated processes in human cells, with particular importance in preventing hyper-recombination events that could lead to genomic instability.

What are the optimal conditions for using RECQ1 antibodies in helicase activity assays?

When conducting helicase activity assays with RECQ1, researchers should optimize several critical parameters based on established protocols. The standard helicase buffer composition includes:

• 20 mM Tris-HCl, pH 7.5

• 8 mM DTT

• 5 mM MgCl₂

• 10 mM KCl

• 10% glycerol

• 80 μg/ml BSA

The reaction typically proceeds with the following steps:

• Pre-incubate RECQ1 with any interacting proteins (POT1, TRF1, TRF2, etc.) in helicase buffer

• Add 32P-labeled substrate DNA

• Incubate for 30 minutes at 37°C

• Stop the reaction with buffer containing 35 mM EDTA, 0.9% SDS, 25% glycerol, and tracking dyes

• Analyze reaction products via non-denaturing PAGE

When studying interactions with telomeric proteins or specific DNA structures, researchers should consider how these factors might modulate RECQ1 activity, as studies have shown both stimulatory and inhibitory effects depending on the interacting partner.

How should researchers design siRNA experiments to study RECQ1 function?

When designing siRNA experiments targeting RECQ1, researchers should implement a comprehensive approach to ensure specificity and effectiveness:

• Validation of knockdown efficiency: Always confirm RECQ1 depletion at both mRNA and protein levels. RT-qPCR protocols should use appropriate primers (concentration ~300 nM) with amplification conditions: 30 seconds at 95°C, followed by 40 cycles of 95°C for 5 seconds and 60°C for 30 seconds . For protein detection, western blot using anti-RECQ1 antibodies at 1:1000 dilution is recommended .

• Controls: Include both non-targeting siRNA controls and functional rescue experiments where possible to confirm phenotype specificity.

• Phenotypic readouts: Based on RECQ1's known functions, key endpoints to measure include:

  • Nascent strand degradation at stalled replication forks

  • Spontaneous and damage-induced γ-H2AX and 53BP1 foci formation

  • Sister chromatid exchange frequency

  • Cell proliferation rate and cell cycle distribution

  • Sensitivity to DNA damaging agents (particularly MMS and TMZ)

• Cell type considerations: The consequences of RECQ1 depletion may vary between cell types due to differential expression of other RecQ helicases that might compensate for RECQ1 loss .

How does RECQ1 expression correlate with cancer outcomes and how can researchers quantify this relationship?

RECQ1 overexpression has been documented in multiple cancer types, with potential prognostic significance. To quantify this relationship, researchers should employ a systematic approach:

• Immunohistochemical analysis: For tissue samples, use polyclonal antibodies against RECQ1 (such as those from Santa Cruz Biotechnology) with antigen retrieval in sodium citrate buffer . For quantification, calculate staining scores by multiplying the intensity of nuclear staining by the percentage of stained areas within tumors .

• Expression correlation with clinical outcomes: Collect comprehensive clinical data including survival information, treatment response, and pathological characteristics. Statistical analysis should include Kaplan-Meier survival curves and multivariate analysis to account for confounding factors .

• Comparative analysis across cancer types: RECQ1 is notably overexpressed in:

  • Glioblastoma multiforme (GBM)

  • Epithelial ovarian cancer

  • Hypopharyngeal cancer

When designing such studies, it's essential to include appropriate non-cancerous control tissues and standardize antibody dilutions and detection methods across samples to enable reliable comparisons.

What is the relationship between RECQ1 function and chemotherapy resistance in cancer cells?

RECQ1 appears to contribute to chemotherapy resistance through its DNA repair functions, particularly in response to alkylating agents. Research findings indicate:

• RECQ1-depleted glioblastoma cells show hypersensitivity to methyl methanesulfonate (MMS) and temozolomide (TMZ)

• RECQ1 depletion results in increased spontaneous γ-H2AX and 53BP1 foci formation in response to MMS exposure, indicating accumulated DNA damage

• RECQ1-PARP1 signaling pathway contributes to the resistance of glioblastoma cells to TMZ, which is currently the standard-of-care chemotherapy agent

To investigate this relationship experimentally, researchers should:

• Establish RECQ1 knockdown or knockout models in cancer cell lines

• Perform dose-response studies with relevant chemotherapeutic agents

• Analyze DNA damage markers, cell cycle progression, and apoptosis indicators

• Consider combination approaches targeting both RECQ1 and interacting partners (particularly PARP1) to enhance chemotherapy efficacy

How does RECQ1 contribute to telomere maintenance in cancer cells utilizing the ALT pathway?

RECQ1 plays a specialized role in cancer cells that utilize the Alternative Lengthening of Telomeres (ALT) pathway instead of telomerase for telomere maintenance:

• Association with telomeric structures: RECQ1 physically associates with telomeres specifically in ALT cells .

• Functional activities at telomeres:

  • Efficiently resolves telomeric D-loops

  • Processes Holliday junction substrates at telomeres

  • Interacts functionally with telomere repeat-binding factor 2 (TRF2), which regulates its helicase activity

• Interaction with telomere-binding proteins:

  • Physical and functional interaction with TRF2

  • Protection of telomeres 1 (POT1) stimulates RECQ1 activity, particularly on telomeric substrates containing thymine glycol, a replicative blocking lesion

When investigating RECQ1's role in ALT, researchers should employ chromatin immunoprecipitation (ChIP) assays using RECQ1 or TRF1 antibodies (5 μg) followed by protein G agarose beads to capture telomeric DNA sequences . This approach can reveal the extent of RECQ1 association with telomeres in different cancer cell types and under various experimental conditions.

How should researchers interpret contradictory results between RECQ1 knockout and knockdown studies?

When facing contradictory results between knockout and knockdown approaches, researchers should consider several factors:

• Compensation mechanisms: Previous studies have shown that genetic knockout of RECQ1 in chicken lymphocyte DT40 cells yielded viable cells with no major defect in sister chromatid exchange (SCE), while RECQ1 siRNA treatment in HeLa cells showed substantial increases in SCEs (17-34 SCEs/cell) . This discrepancy may be explained by:

  • Cell-type specific differences in the abundance of other RecQ helicases

  • Long-term adaptation in knockout models versus acute depletion in knockdown

  • Functional redundancy among RecQ family proteins, as suggested by the observation that double knockout (RECQL1−/−, BLM−/−) cells showed more severe phenotypes than single knockouts

• Technical considerations:

  • Verify the completeness of protein depletion in both systems

  • Consider the timing of analysis (immediate versus long-term effects)

  • Examine the specific endpoints measured in each study

To resolve such contradictions, researchers should perform complementary approaches, including both acute (siRNA) and chronic (CRISPR-Cas9) depletion strategies, combined with rescue experiments using wildtype or mutant RECQ1 constructs.

What statistical approaches are recommended for analyzing RECQ1-related experimental data?

Based on published RECQ1 research, the following statistical approaches are recommended:

• For cell-based experiments:

  • Present data as mean ± standard deviation (SD) from at least three independent experiments

  • Use Student's independent t-test for comparing two experimental groups

  • Consider two-sided p-values with significance threshold set at P < 0.05

  • Use GraphPad Prism software (or equivalent) for statistical analyses

• For clinical correlation studies:

  • Use appropriate multivariate regression models to account for confounding variables

  • Apply Kaplan-Meier survival analysis with log-rank tests for time-to-event data

  • Consider non-parametric tests when data do not follow normal distribution

• For biochemical assays:

  • Include appropriate positive and negative controls in each experiment

  • Perform quantitative analysis using densitometry for western blots or fluorescence intensity measurements

  • Consider dose-response relationships and calculate EC50/IC50 values when applicable

When reporting results, clearly state the specific statistical tests used, exact p-values, and confidence intervals where appropriate.